Phase I Trial of a Combination of the Multikinase Inhibitor Sorafenib and the Farnesyltransferase Inhibitor Tipifarnib in Advanced Malignancies
Open accessThe DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
Purpose: We evaluated the safety, maximum tolerated dose, pharmacokinetics, and biological effects of the combination of the Raf-1, RET, KIT, platelet-derived growth factor receptor, and vascular endothelial growth factor receptor 2 kinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib. Experimental Design: A standard 3 + 3 phase I dose-escalation design was used with a 28-day cycle (sorafenib daily and tipifarnib for 21 days, by mouth). Results: Fifty patients were treated; 43 reached restaging evaluation after cycle 2. The most common side effects were grade 1 to 2 rash, hyperglycemia, and diarrhea. Dose-limiting toxicity was rash, and the recommended phase II dose is sorafenib 400 mg p.o. qam/200 mg p.o. qpm and tipifarnib p.o. 100 mg bd. Despite the low doses of tipifarnib, one quarter of patients had 50 reduction in farnesyltransferase levels. Interestingly, six of eight patients with medullary thyroid cancer had durable stable disease (n = 3) or partial remissions (n = 3), lasting 12 to 26+ months. Five of the six responders had available tissue, and RET gene mutations were identified in them. Prolonged (6 months) stable disease was also seen in nine patients as follows: papillary thyroid cancer (n = 4; 18+ to 27+ months), adrenocortical cancer (n = 2; 7 and 11 months), and one each of melanoma (platelet-derived growth factor receptor mutation positive; 14 months), renal (6 months), and pancreatic cancer (6 months). Conclusions: Our study shows that the combination of tipifarnib and sorafenib is well tolerated. Activity was seen, especially in patients with medullary thyroid cancer, a tumor characterized by RET mutations. (Clin Cancer Res 2009;15(22):70618)
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Drug target identification using side-effect similarity
Campillos, M., Kuhn, M., Gavin, A.-C., Jensen, L. J., & Bork, P. (2008) · Science · doi:10.1126/science.1158140 · Cited by 1,248
Cited by
Ras in Cancer and Developmental Diseases
Fernandez-Medarde, A., & Santos, E. (2011) · Genes & Cancer · doi:10.1177/1947601911411084 · Cited by 897
Else, T., Kim, A. C., Sabolch, A., Raymond, V. M., Kandathil, A., Caoili, E. M., Jolly, S., Miller, B. S., Giordano, T. J., & Hammer, G. D. (2014) · Endocrine Reviews · doi:10.1210/er.2013-1029 · Cited by 892
RET Aberrations in Diverse Cancers: Next-Generation Sequencing of 4,871 Patients
Kato, S., Subbiah, V., Marchlik, E., Elkin, S. K., Carter, J. L., & Kurzrock, R. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1679 · Cited by 282
Self-citationCalcitonin as a biomarker of C cell disease: recent achievements and current challenges
Costante, G., & Meringolo, D. (2020) · Endocrine · doi:10.1007/s12020-019-02183-6 · Cited by 41
Farnesyltransferase inhibitors: where are we now?
Tsimberidou, A. M., Chandhasin, C., & Kurzrock, R. (2010) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2010.535516 · Cited by 39
“Prolonged (‡ 6 months) SD was also seen in nine patients as follows: papillary thyroid cancer (n = 4; over 18 to over 27 months), adrenocortical cancer (n = 2; 7 and 11 months), and one each of melanoma (PDGFR-mutation-positive; 14 months), renal (6 months), and pancreatic cancer (6 months) [54].”
BackgroundResultSelf-citation
Metadata
- Authors
- Hong, D. S., Sebti, S. M., Newman, R. A., Blaskovich, M. A., Ye, L., Gagel, R. F., Moulder, S., Wheler, J. J., Naing, A., Tannir, N. M., Ng, C. S., Sherman, S. I., El Naggar, A. K., Khan, R., Trent, J., Wright, J. J., & Kurzrock, R.
- Venue
- Clinical Cancer Research
- Published
- 2009-11-11
- Volume
- 15
- Issue
- 22
- Pages
- 7061-7068
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- OpenAlex
- W2138396354
- Cited by
- 82
- References
- 1
- FWCI
- 5.22
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Phase I Trial of a Combination of the Multikinase Inhibitor Sorafenib and the Farnesyltransferase Inhibitor Tipifarnib in Advanced Malignancies. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-09-1241
- The paper
- Hong, D. S., Sebti, S. M., Newman, R. A., Blaskovich, M. A., Ye, L., Gagel, R. F., Moulder, S., Wheler, J. J., Naing, A., Tannir, N. M., Ng, C. S., Sherman, S. I., El Naggar, A. K., Khan, R., Trent, J., Wright, J. J., & Kurzrock, R. (2009). Phase I Trial of a Combination of the Multikinase Inhibitor Sorafenib and the Farnesyltransferase Inhibitor Tipifarnib in Advanced Malignancies. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-09-1241
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.